公开(公告)号：WO2021195548A1

公开(公告)日：2021-09-30

申请号：PCT/US2021/024453

申请日：2021-03-26

Applicant: TRAVECTA THERAPEUTICS, PTE. LTD.

Inventor： SILVER, David Lawrence ,  AHMED, Mahmood ,  MAK, Sing Yeung Frankie

IPC: C07F9/09 ,  A61K31/661 ,  A61P17/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  C07F9/091

Abstract: The present application provides oleoylethanolamide compounds useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating diseases or disorders are also provided.

公开(公告)号：WO2021195555A1

公开(公告)日：2021-09-30

申请号：PCT/US2021/024470

申请日：2021-03-26

Applicant: TRAVECTA THERAPEUTICS, PTE. LTD.

Inventor： AHMED, Mahmood ,  MAK, Sing Yeung Frankie ,  SILVER, David Lawrence

IPC: A61P9/00 ,  A61P17/00 ,  A61P25/00 ,  C07F9/09 ,  A61K31/661 ,  C07F9/091

Abstract: The present application provides palmitoylethanolamide compounds useful for treating a disease or disorder in a subject in need thereof. Pharmaceutical compositions comprising the compounds and methods of treating diseases or disorders are also provided.

公开(公告)号：WO2022115645A1

公开(公告)日：2022-06-02

申请号：PCT/US2021/060877

申请日：2021-11-24

Applicant: AKAGERA MEDICINES, INC.

Inventor： DRUMMOND, Daryl C. ,  KIRPOTIN, Dmitri B. ,  HAYES, Mark E. ,  KOSHKARYEV, Alexander ,  FULTON, Ross B.

IPC: A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K47/08 ,  C07C327/06 ,  C07C327/22 ,  C07D317/28 ,  C07F9/091 ,  C11B3/10 ,  C11C3/003

Abstract: The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

公开(公告)号：WO2022251177A2

公开(公告)日：2022-12-01

申请号：PCT/US2022/030674

申请日：2022-05-24

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： BOUREZG, Zouaoui ,  POUSSET, Cyrille

IPC: A61K31/661 ,  A61K9/08 ,  A61P3/02 ,  A61P3/12 ,  C07F9/11 ,  A61K9/0029 ,  A61L2/0023 ,  C07F9/091

Abstract: The present disclosure relates to a pharmaceutical composition for providing phosphorus to an adult or pediatric patient, wherein the composition is an aqueous solution of sodium glycerophosphate which by virtue of an improved process for producing the active pharmaceutical ingredient and the pharmaceutical composition is characterized by a low amount of free phosphate, a low amount of SGP-related substances and by a low amount of aluminum. The pharmaceutical composition is used in clinical nutrition, preferably in the preparation of nutritional formulations by compounding. The compositions can further be used for preventing or correcting phosphorus deficiency (hyperphosphatemia) in said adult or pediatric patients.

公开(公告)号：WO2022002040A1

公开(公告)日：2022-01-06

申请号：PCT/CN2021/103076

申请日：2021-06-29

Applicant: SUZHOU ABOGEN BIOSCIENCES CO., LTD.

Inventor： YING, Bo

IPC: A61P35/00 ,  A61K9/127 ,  C12N15/00 ,  A61K31/7088 ,  A61K47/00 ,  C07F9/09 ,  C07F9/24 ,  C07F9/553 ,  C07F9/568 ,  C07F9/572 ,  C07F9/59 ,  C07F9/6512 ,  C07F9/6533 ,  C07F9/6558 ,  C07F9/6561 ,  A61K31/7105 ,  A61K31/7115 ,  A61K47/02 ,  A61K9/0019 ,  A61K9/1272 ,  C07F9/091 ,  C07F9/2458 ,  C07F9/5532 ,  C07F9/5728 ,  C07F9/65583 ,  C07F9/65586

Abstract: Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipids.